ORIC Pharmaceuticals, Inc. (ORIC) Analyst Estimates Annual - Discounting Cash Flows
ORIC
ORIC Pharmaceuticals, Inc.
ORIC (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
Number of Analysts 7 8 9 11 0 0
Estimated Revenue
Low 59 19.35 2.58 8.22 0 0
Average 59 19.35 2.58 8.22 0 0
High 59 19.35 2.58 8.22 0 0
Estimated EBITDA
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EBIT
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated Net Income
Low -103.7 -141.5 -140.6 -138.8 -117.3 -130.5
Average -103.7 -114.4 -114.7 -115.4 -114 -129.1
High -103.7 -87.16 -88.82 -92.02 -110.6 -127.7
Estimated SGA Expenses
Low 0 0 0 0 0 0
Average 0 0 0 0 0 0
High 0 0 0 0 0 0
Estimated EPS
Low -1.49 -2.03 -2.02 -1.99 -1.68 -1.87
Average -1.49 -1.68 -1.62 -1.59 -1.62 -1.85
High -1.49 -1.25 -1.27 -1.32 -1.59 -1.83
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program